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BACKGROUND & AIMS: Immunotherapy using dendritic cells (DCs) is a promising 
cancer therapy. The success of this therapy depends on the function of induced DCs. 
However, there has been no consensus on optimal conditions for DC preparation in vitro 
for immunotherapy of hepatocellular carcinoma (HCC) patients. To address relevant 
issues, we evaluated the procedures to induce DCs that efficiently function in hepatitis 
C virus (HCV)-related HCC.  
METHODS: We studied immunological data from 14 HCC patients. The DC 
preparation and the surface markers were assessed by flow cytometric analysis. Four 
different additional activation stimuli (method I, medium alone; method II, with 
OK-432; method III, with IL-1β + IL-6 + TNF-α; method IV, with IL-1β + IL-6 + 
TNF-α + PGE2) were tested and the functions of DCs were confirmed by examination 
of the ability of phagocytosis, cytokine production and allogeneic mixed lymphocyte 
reaction (MLR). 
RESULTS: The numbers of DCs induced and their cytokine production ability were 




DCs in MLR was significantly lower in HCC patients than in healthy controls. The 
maturation of DCs with OK-432 boosted production of cytokines and chemokines, such 
as IL-2, IL-12p70, IFN-γ, TNF-α, IL-13 and MIP1α, and restored T-cell stimulatory 
activity of DCs in MLR. 
CONCLUSIONS: The clinically approved compound OK-432 is a candidate for highly 
immunocompetent DC preparation and may be considered as a key drug for 
immunotherapy of HCV-related HCC patients. 
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Hepatocellular carcinoma (HCC) is the seventh most common cancer worldwide and 
the fourth leading cause of cancer-related death in Japan [1]. Hepatitis C virus (HCV) 
infection is the common cause of chronic liver disease and leads to liver cirrhosis, 
contributing to the incidence of HCC [2]. Although some therapies for HCC exist, 
tumor recurrence rates are extremely high in these patients after curative treatments, 
including hepatic resection and radiofrequency ablation (RFA) [3]. In terms of the 
reason of this, HCV-related chronic hepatitis and cirrhosis are known to have 
carcinogenic potential for the development of HCC [4]. For the secondary 
chemoprevention of HCC patients with HCV-related cirrhosis, recent studies showed 
the efficacy of long-term and low-dose interferon-α therapy [5]. Among many strategies 
for HCC recurrence, immunotherapy is considered to be an attractive strategy to 
eradicate tumor cells completely [6]. 
Until now, different immunotherapeutic approaches have been tested for patients with 
HCC [7]. However, tumors have evolved numerous immune escape mechanisms, 
including the generation of cells with immune suppressor functions, such as Tregs and 




professional antigen-presenting cells with the unique ability to initiate and maintain 
adaptive immunity, and are considered to overcome the immune-suppressive 
environment produced by tumors [9, 10]. DCs are also known to enhance antitumor 
immunity by activating the functions of endocytosis, trafficking, maturation and 
cytokine production. Numerous studies have shown that DCs from peripheral blood of 
HCC patients are reduced in number, have an immature phenotype and an impaired 
function [11]. Moreover, to date, there is no consensus on optimal conditions for DC 
preparation in vitro for immunotherapy of HCC patients. 
Recently, we have developed the combined immunotherapy of transcatheter hepatic 
arterial embolization (TAE) with infusion of immature and mature monocyte-derived 
DCs (MoDCs) for HCC [12, 13]. In this study, we evaluated the procedures to induce 





MATERIALS AND METHODS 
 
Patients and healthy controls 
Fourteen patients (four women and ten men) attending Kanazawa University Hospital 
(Ishikawa, Japan) between September 2007 and December 2008 were enrolled in this 
study. All patients were serologically positive for HCV. HCC was radiologically 
diagnosed by computed tomography (CT), magnetic resonance imaging (MRI) and CT 
angiography. Blood samples were taken from 14 patients with HCC and 14 healthy 
controls having no hepatitis history and serologically negative for both hepatitis B and 
C. The clinical profiles of the patients and controls analyzed in the present study are 
shown in Table 1. All patients gave written informed consent to participate in the study 
in accordance with the Helsinki declaration and this study was approved by the regional 
ethics committee (Medical Ethics Committee of Kanazawa University, No. 829). 
  
Preparation of immature DCs 
Immature DCs were separated from peripheral blood mononuclear cells (PBMCs) of 
patients and healthy controls. PBMCs were isolated by centrifugation using 




serum-free medium (GMP CellGroR DC Medium; CellGro, Manassas, VA) and allowed 
to adhere to 6-well tissue culture dishes (Costar, Cambridge, MA) at 1.4 x 107 cells in 
2mL per well. After 2 h at 37°C, non-adherent cells were removed and adherent cells 
were cultured in the medium with 50 ng/mL recombinant human IL-4 (GMP grade; 
CellGroR) and 100 ng/mL recombinant human GM-CSF (GMP grade; CellGroR) for 5 
days to generate immature DCs.  
 
Activation of immature DCs 
Several activation stimuli were tested (Figure 1). After 5 days of culture, the 
immature DCs induced by the above method were cultured for 2 additional days in the 
serum-free medium (method I) or stimulated with 0.1 KE/mL OK-432 (Chugai 
Pharmaceuticals, Tokyo, Japan) (method II), 10 ng/mL IL-1β (GMP grade; CellGroR), 
100 ng/mL IL-6 (GMP grade; CellGroR) and 20 ng/mL TNF-α (GMP grade; CellGroR) 
(method III), and IL-1β, IL-6, TNF-α and PGE2 (Kaken Pharmaceuticals, Tokyo, Japan) 
(method IV). On day 7, the cells were harvested. 
 
Antibodies 




cytometry: anti-lin1 (lineage cocktail 1; CD3, CD14, CD16, CD19, CD20 and 
CD56)-FITC, anti-HLA-DR-PerCP and -FITC (L243), anti-CD11c-APC (S-HCL-3), 
anti-CD123-PE (9F5), anti-CCR7-PE (3D12), anti-CD14-APC (MφP9) (BD 
Biosciences Pharmingen, San Jose, CA), anti-CD80-PE (MAB104), anti-CD83-PE 
(HB15a) and anti-CD86-PE (HA5.2B7) (Beckman Coulter, Fullerton, CA). 
 
Flow cytometric analysis 
Surface markers on DCs were evaluated using flow cytometric analysis. Cells were 
analyzed on a FACSCaliburTM for four-color flow cytometry. Data analysis was 
performed using CELLQuestTM software (Becton Dickinson, San Jose, CA).  
 
Endocytosis assay 
The endocytic capacity of DCs was assessed by measurement of FITC dextran 
(Sigma-Aldrich, St. Louis, MO) uptake. DCs were incubated for 30 min at 37°C in the 
presence of 1 mg/mL FITC dextran, washed three times and analyzed using a 
FACSCaliburTM cytometer. 
 




The concentrations of cytokines and chemokines in the supernatants of culture 
medium were measured using enzyme-linked immunosorbent assay (ELISA) kit for 
IL-12p40 and IFNγ (Biosource International, Camarillo, CA) and the Bioplex assay 
(Bio-Rad, Hercules, CA) according to the manufacturers’ instructions.  
 
Allogeneic mixed lymphocyte reaction (allo-MLR) 
To evaluate the immune-stimulatory function of DCs after different stimulations, 
allogeneic mixed lymphocyte reaction (allo-MLR) was performed. 1×104 irradiated 
DCs (25 Gy) and 1×105 allogeneic PBMCs from a healthy donor were suspended in 
200μL of serum-free medium (GMP CellGroR DC Medium) and co-cultured in 96-well 
round-bottomed microplates. After 2 days at 37°C, 1 μCi of [3H]-thymidine (Amersham 
Pharmacia Biotech, Piscataway, New Jersey) was added to each well. The amount of 
incorporated [3H]-thymidine was counted using a liquid scintillation counter (Beckman 
Coulter, Palo Alto, California). Results are expressed as the stimulation index (counts 
per minute in the presence of DCs divided by counts per minute in the absence of DCs).  
 
Statistical analysis 




between groups was determined by applying the Mann-Whitney U test and unpaired t 







Yield and phenotype of DCs in patients and healthy controls 
Adherent cells separated from PBMCs were cultured in the presence of IL-4 and 
GM-CSF, and harvested on day 7 (Method I). These harvested cells, which showed high 
levels of MHC class II (HLA-DR) and the absence of marker for mature monocytes 
(CD14), were consistent with the cell surface markers of DCs. The yield of DCs was 
variable, ranging from 23% to 28% of the initial PBMC population, and indicated no 
significant difference between healthy controls and HCC patients (Figure 2A). We next 
analyzed the surface markers, which classified DCs as myeloid or plasmacytoid DCs, 
on these lineage marker (lin1)-negative and HLA-DR-positive (lin1-HLA-DR+) DCs. In 
both patients and controls, the majority of DCs expressed CD11c and the percentages of 
the DCs classified to the myeloid subset (CD11c+CD123-) were not different among the 
two groups (Figure 2B).  
Subsequently, we analyzed the expression of co-stimulatory molecules, including 
B7-1 (CD80), B7-2 (CD86), an activation marker (CD83) and a chemokine receptor 
(CCR7) by recording geometric mean fluorescence intensities (MFIs) (Figure 2C). 




(204.5 ± 120.5, P < .05) compared with that of healthy controls (97.7 ± 42.3). The 
expression levels of CD80, CD83 and CCR7 were similar in two groups.   
 
Functions of DCs in patients and healthy controls 
The endocytic and phagocytic capacities of DCs were assessed by measurement of 
FITC dextran uptake using flow cytometry. A representative result is shown in Figure 
3A. MFIs of DCs induced from PBMCs of HCC patients indicate more FITC dextran 
uptake than those from healthy controls (223.3 ± 82.9 vs. 113.1 ± 35.4, P < .05).  
Next, we analyzed their ability to produce inflammatory cytokines that influence 
T-cell function. The spontaneous IL-12p40 production of DCs was measured using an 
enzyme-linked immunosorbent assay (ELISA) (Figure 3B). The concentrations of 
IL-12p40 in the supernatant did not differ between HCC patients and healthy controls 
(11.4 ± 3.2 vs. 14.2 ± 7.5, P = .29). 
In contrast, regarding T-cell stimulatory activity of DCs in allogeneic MLR, which 
was expressed as stimulation index value of [3H]-thymidine incorporation at the 
T-cell/DC ratio of 10/1, the index values were significantly lower in HCC patients than 





Yield and phenotype of DCs with different stimulations 
Considering effective antitumor immunity of DC-based immunotherapy, maturational 
status and T-cell stimulatory potential of DCs are important. Therefore, we next 
examined the effects of different maturation stimuli on the phenotypes and the functions 
of DCs induced from PBMCs in HCC patients. As shown in Figure 1, PBMCs of HCC 
patients were differentiated into immature DCs in the presence of IL-4 and GM-CSF on 
day 5 and then harvested on day 7 after culturing for two additional days in several 
activation stimuli.  
First, the expressions of HLA-DR, various costimulatory molecules and chemokine 
receptor, which were the indicators of DC maturation, were assessed (Figure 4). By 
culturing with the additional stimuli (Methods II, III and IV), the percentage of 
CD14-HLA-DR+ DCs was significantly increased compared with that in the medium 
alone (Method I) (Figure 4A). However, the percentage of CD11c+CD123- DCs was not 
different in all groups.  
In the next step, we assessed the geometric mean fluorescence intensities of CD80, 
CD83, CD86 and CCR7 (Figure 4B). The expressions of CD80 and CD86 of DCs with 
the stimulation (Methods II, III and IV) increased significantly compared with those 




II) or cytokine cocktail with PGE2 (Method IV) showed a significant increase of CD80 
and CD86 in comparison with those stimulated with cytokine cocktail without PGE2 
(Method III). The expression level of CD83 was increased by OK-432 (Method II) and 
cytokine cocktail with PGE2 (Method IV) stimulation. The expression of CCR7 was not 
different among the groups. 
 
Function of DCs with different stimulations 
Initially, the change of phagocytic capacity of DCs induced from PBMCs in HCC 
patients was assessed by the same protocol (shown above) (Figure 5A). The uptake of 
FITC dextran of DCs stimulated with OK-432, cytokine cocktail with and without 
PGE2 (Methods II, III and IV) was decreased significantly compared with that of DCs 
cultured in medium alone (Method I) (P < .05).  
Next, we also examined cytokine production, such as IL-12p40 and IFN-γ, of DCs by 
ELISA (Figure 5B). The DCs stimulated with OK-432 (Method II) produced much 
more IL-12p40 and IFN-γ than the DCs stimulated with cytokine cocktail with and 
without PGE2 (Methods IV and III, respectively) or medium alone (Method I) (P < .05). 
In the analysis of IFN-γ production, the DCs stimulated with OK-432 (Method II) 





Allo-stimulatory capacity of DCs with different stimulations 
To assess whether the enhanced expression of costimulatory molecules reflects the 
antigen presentation capacity, we studied the function using an allo-MLR (Figure 5C). 
Stimulation with OK-432 (Method II) or cytokine cocktail with PGE2 (Method IV) was 
more efficient in inducing T-cell proliferation than that with cytokine cocktail without 
PGE2 (Method III) or medium alone (Method I). Moreover, the index value of DCs 
stimulated with OK-432 was significantly higher than that of DCs stimulated with 
cytokine cocktail with PGE2 (9.9 ± 3.9 vs. 4.7 ± 1.7, P < .05).  
To evaluate the mechanism of strong allo-stimulatory capacity of DCs induced by 
OK-432 in HCC patients, the cytokine levels in allogeneic MLR supernatant were 
examined using Bioplex assay (Figure 6). The levels of cytokines in the medium 
containing DCs with OK-432 stimulation (Method II), such as IL-2, IL-12p70, IFN-γ, 
TNF-α, IL-13 and MIP1α, were significantly higher than those in the medium 
containing DCs with medium alone (Method I) (P < .05) (Figure 6A). In addition to an 
increase of these cytokines and chemokines, other cytokines including IL-4, IL-10 and 
IL-17 were also significantly increased in the medium in which DCs with OK-432 







Immunotherapy is a promising therapy for HCC patients and a number of the 
therapies have been evaluated [14]. Among the numerous immune cells, DCs are the 
most potent type of antigen-presenting cells in the human body. However, impaired 
function of DCs has been implicated in the escape of the tumor from immune control in 
cancer patients [15]. In chronic HCV-infected patients, recent studies have shown that 
the function of MoDCs is not necessarily impaired [16], while several groups have 
reported a maturation defect and impaired function in HCC patients [17].  
In the present study, the number and cell surface maturation markers of harvested 
DCs derived from PBMCs of HCC patients are not different from those of healthy 
controls. In particular, the results that the percentage of CD11c+CD123- myeloid DCs 
was not different suggested that the culture method using IL-4 and GM-CSF is suitable 
for the induction of effective DCs in HCC immunotherapy. Because myeloid DC is a 
main player that produces cytokines such as IL-12, induces T-helper type 1 (Th1) 
response and antigen-specific cytotoxic T-cell immunity [18].  
In the analysis of maturation markers, the DCs in HCC patients showed similar 




compared with the DCs in healthy donors. However, the result of FITC dextran uptake 
indicated that the DCs in HCC patients showed high ability, suggesting that their 
functional phenotype is still immature. Consistent with these results, stimulatory 
capacity of these DCs in MLR was lower than that of healthy controls, suggesting that 
additional treatment is required for optimal DC preparation. 
Unfortunately, there is still no consensus on the optimal procedure for preparation of 
DCs using the drugs with good manufacturing practice (GMP) grade. For the clinical 
application of DC-based immunotherapy, it is desirable to use maturation agents with 
GMP grade for the safety of patients. Therefore, in this study, we evaluated the 
procedures using GMP-grade compounds. OK-432, a penicillin-inactivated and 
lyophilized preparation of Streptococcus pyrogenes, was reported to be 
immunomodulatory and have potential therapeutic properties for cancer immunotherapy 
[19, 20]. DCs stimulated with OK-432 have been suggested to acquire a mature 
phenotype, produce a significant amount of T-helper type 1 (Th1) cytokines such as 
IL-12 and IFNγ and enhance cytotoxic T-lymphocyte activity [21]. Otherwise, many 
cytokines, often containing pro-inflammatory mediators, or their combinations have 
been tested for DC maturation. Since 1997, cytokine cocktails containing TNF-α, IL-1β, 




PGE2 to the maturation cocktail was reported to enhance further CCR7 expression, 
migration capacity and T-cell stimulatory activity of DCs even in patients with 
advanced cancer [23]. In this study, on the basis of these results, we analyzed DCs 
derived from PBMCs of HCV-related HCC patients by OK-432 or cytokine cocktails. 
Both methods, using OK-432 or cytokine cocktails, had success in enhancing the 
expression levels of CD80, CD83 and CD86. The phagocytic capacity of the DCs 
induced by both methods was lower than that of the DCs induced by a standard method. 
On the other hand, the production of cytokines such as IL-12p40 and IFN-γ and 
allostimulatory capacity were excellent in DCs with OK-432 stimulation. These results 
suggest that both methods are useful for maturation, but OK-432 stimulation is the best 
method of DC preparation for immunotherapy in HCV-related HCC patients. Moreover, 
the types of cytokines and chemokines detected in allogeneic MLR were very similar to 
those that we previously reported in serum of patients who received immunotherapy 
with OK-432-stimulated DCs [13]. Taken together with these results, the DCs 
stimulated with OK-432 may have immunological potential in not only local but also 
systemic responses through cytokine production.  
In conclusion, the results of the present study suggest that the clinically approved 




HCV-related HCC patients and should provide us with a novel insight for 
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Figure 1: Protocols for preparation of DCs. DCs, which were derived from PBMCs in 
the presence of IL-4 and GM-CSF for five days, were cultured for 2 additional days 
with the serum-free medium only (Method I), OK-432 (Method II), and cytokine 
cocktails consisting of IL-6, IL-1β and TNF-α without (Method III) or with (Method 
IV) PGE2. On day 7, these cells were harvested and evaluated. 
 
Figure 2: The yield and characteristics of DCs derived from PBMCs in the presence of 
IL-4 and GM-CSF (Method I). (A) The yield of CD14-HLA-DR+ DCs in healthy 
controls and HCC patients, which was calculated as a percentage of the cells gated on 
side and forward scatter. (B) The yield of CD11c+CD123- myeloid DCs in healthy 
controls and HCC patients, which was calculated as a percentage in lin1-HLA-DR+ cells. 
(C) Analysis of cell surface markers of lin1-HLA-DR+ DCs in healthy controls and HCC 
patients. Data are expressed as mean fluorescence intensity (MFI) ± SD. White and 





Figure 3: Analysis of functions of DCs. (A) The phagocytic capacity of DCs was 
assessed by measurement of FITC dextran uptake by flow cytometry. A representative 
analysis is shown in the left panel. The shaded curves indicate MFIs of DCs incubated 
with FITC dextran for 30 min at 37°C, and the unshaded curves are those of control 
DCs incubated without FITC dextran at the same time. MFIs of positive cells in healthy 
controls (white bar) and HCC patients (black bar) are indicated in the right panel. Data 
are expressed as MFI ± SD. (B) The capacity of cytokine production of DCs in healthy 
controls and HCC patients. (C) T-cell stimulatory capacity of DCs was evaluated by 
allogeneic MLR. White and black bars indicate healthy controls and HCC patients, 
respectively. *P < .05. 
 
Figure 4: Comparison of the yield and phenotype of DCs induced from PBMCs of 
HCC patients using 4 kinds of methods. (A) The yields of CD14-HLA-DR+ and 
CD11c+CD123- DCs are shown in left and right panels, respectively. (B) The surface 
markers consisting of CD80, CD83, CD86 and CCR7 on DCs were evaluated by flow 
cytometry. White, black, gray and hatched bars indicate the methods of DC maturation 
with methods I, II, III and IV, respectively. The methods of DC maturation are shown in 





Figure 5: Comparison of the functions of DCs induced from PBMCs of HCC patients 
using 4 kinds of methods. (A) The phagocytic capacity of DCs was evaluated by the 
uptake of FITC dextran using flow cytometry. (B) The capacity of cytokine production 
of DCs was measured by ELISA. (C) T-cell stimulatory capacity of DCs was evaluated 
by allogeneic MLR. White, black, gray and hatched bars indicate the methods of DC 
maturation with methods I, II, III and IV, respectively. The methods of DC maturation 
are shown in Figure 1. *P < .05. 
 
Figure 6: Cytokine production of DCs induced from PBMCs of HCC patients with and 
without OK-432 stimulation in MLR. The cytokine levels of culture supernatants in 
allogeneic MLR were assessed by Bioplex assay. As controls, supernatants of medium 
cultured with PBMCs alone and DCs alone with and without OK-432 stimulation were 
used. (A) The concentrations of cytokines and chemokines such as IL-2, IL-12p70, 
IFN-γ, TNF-α, IL-13 and MIP1α in the medium cultured with 5 different conditions as 
indicated below. (B) The concentrations of cytokines such as IL-4, IL-10 and IL-17 
were significantly higher in the medium cultured with OK-432-stimulated DCs and 




gray and black bars indicate the cytokine levels in the medium cultured with PBMCs 
alone, OK-432-unstimulated DCs alone, OK-432-stimulated DCs alone, 
OK-432-unstimulated DCs with PBMCs and OK-432-stimulated DCs with PBMCs, 





Table 1  Characteristics of healthy controls and patients 
 Controls a HCC patients P b 
No. of patients 14 14  
Age (years) 42.6±14.9 68.8±7.6 < .05 
Gender (M/F) 7/7 10/4 n.s. 
WBC (X102/µL) ND 43.5±15.4 n.s. 
PLT (X104/µL) ND 13.1±6.0 n.s. 
PT (%) ND 85.2±13.3 n.s. 
ALT (IU/L) ND 59.7±46.8 n.s. 
Alb (g/dL) ND 3.3±0.6 n.s. 
T-Bil (mg/dL) ND 0.8±0.4 n.s. 
Histology of non-tumor liver 
chronic hepatitis 


















Data are expressed as the mean ± SD. 
a ND: not determined, b n.s.: not significant.  
 






